Multifocal motor neuropathy

Current Opinion in Neurology

Volumn 26, Issue 5, 2013, Pages 503-509

  Guimarães Costa, Raquel ^a   Bombelli, Francesco ^a   Léger, Jean Marc ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOSPORIN; ECULIZUMAB; GANGLIOSIDE GM1 ANTIBODY; HEPARIN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; UNCLASSIFIED DRUG;

ABNORMAL SENSATION; ANTIBODY PRODUCTION; BRACHIAL PLEXUS; BRAIN ELECTROPHYSIOLOGY; CEREBROSPINAL FLUID; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; CROSS REACTION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FASCICULATION; FATIGUE SEVERITY SCALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MAINTENANCE THERAPY; MOTONEURON; MOTOR NEUROPATHY; MUSCLE ACTION POTENTIAL; MUSCLE ATROPHY; MUSCLE CRAMP; MUSCLE WEAKNESS; NERVE BLOCK; NERVE FIBER DEGENERATION; NERVE STIMULATION; NEUROLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; POLYNEUROPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; TENDON REFLEX; VIBRATION SENSE;

AUTOANTIBODIES; DISACCHARIDES; HEPARIN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; NEURAL CONDUCTION; POLYNEUROPATHIES; TREATMENT OUTCOME;

EID: 84883827815     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328364caca     Document Type: Review

References (54)

1. Roth G, Roth J, Oschner F. Motor neuropathy with proximal multifocal persistent block, fasciculations and myokyma. Evolution to tetraplegia. Eur Neurol 1986; 25:416-423.
2. Chad DA, Hammer K, Sargent J. Slow resolution of multifocal weakness and fasciculation: A reversible motor neuron syndrome. Neurology 1986; 36:1260-1263.
3. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988; 24:73-78.
4. Feldman EL, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 1991; 30:397-401.
5. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: Current concepts and controversies. Muscle Nerve 2005; 31:663-680.
6. Cats EA, Van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010; 75:818-825.
7. Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: The diagnosis spectrum and response to treatment. Neurology 2007; 69:1680-1687.
8. Léger JM, Beaudet R, Bonné lye G. Prise en charge des neuropathies motrices multifocales avec blocs de conduction en France en 2005. Rev Neurol 2006; 162 (HS1):3S27-3S45.
9. Moroni I, Bugiani M, Ciano C, et al. Childhood-onset multifocal motor neuropathy with conduction blocks. Neurology 2006; 66:922-924.
10. Ramdas S, Prasad M, Spillane K, Kirkpatrick M. Acute motor neuropathy with pure distal involvement -A case report of multifocal motor neuropathy. Eur J Paediatr Neurol 2013; 17:415-418.
11. Van Schaik IN, Leger JM, Nobile-Orazio E, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society -first revision. Joint Task Force of the EFNS and the PNS. J Peripher Nerv Syst 2010; 15:295-301.
12. Léger JM, Vargas S. Neuropathie motrice multifocale avec blocs de conduction persistants: Une neuropathie dysimmunitaire chronique. Presse Med 2006; 35:720-727.
13. Lievens I, Fournier E, Viala K, et al. Multifocal motor neuropathy: A retrospective study of sensory nerve conduction velocities in long-term follow-up of 21 patients. Rev Neurol 2009; 165:243-248.
14. Delmont E, Benaím C, Launay M, et al. Do patients having a decrease in SNAP amplitude during the course of MMN present with a different conditioñ. J Neurol 2009; 256:1876-1880.
15. Straver DCG, Van Asseldonk JTH, Notermans NC, et al. Cold paresis in multifocal motor neuropathy. J Neurol 2011; 258:212-217.
16. Cavaletti G, Zincone A, Marzorati L, et al. Rapidly progressive multifocal motor neuropathy with phrenic nerve paralysis: Effect of nocturnal assisted ventilation. J Neurol 1998; 245:613-616.
17. Delmont E, Azulay JP, Giogi R, et al. Multifocal motor neuropathy with and without conduction block. A single entity?. Neurology 2006; 67:592-596.
18. Attarian A, Azulay JP, Verschueren A, Pouget J. Magnetic stimulation using a triple-stimulation technique in patients with multifocal neuropathy without conduction block. Muscle Nerve 2005; 32:710-714.
19. Deroide N, Uzenot D, Verschueren A, et al. Triple-stimulation technique in multifocal neuropathy with conduction block. Muscle Nerve 2007; 35:632-636.
20. Van Asseldonk JHT, Van den Berg LH, Van den Berg-Vos RM, et al. Criteria for conduction block based on computer simulation studies of nerve conduction with human data obtained in the forearm segment of the median nerve. Brain 2006; 129:2447-2460.
21. Van den Berg-Vos RM, Van den Berg LH, Franssen H, et al. Multifocal inflammatory demyelinating neuropathy: A distinct clinical entity?. Neurology 2000; 54:26-32.
22. Buchwald B, Franssen H, Hughes RAC, et al. 79th ENMC International Workshop: Multifocal motor neuropathy: 14-15 April 2000, Hilversum, the Netherlands. Neuromuscul Disord 2001; 11:309-314.
23. Olney RK, Lewis RA, Putnam TD, Campellone JVJ. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 2003; 27:117-121.
24. Vlam L, Van der Pol WL, Cats E, et al. Multifocal motor neuropathy: Diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 2012; 8:48-58.
25. Cats EA, Jacobs BC, Yuki N, et al. Multifocal motor neuropathy. Association of anti-GM1 IgM antibodies with clinical features. Neurology 2010; 75:1961-1967.
26. Willison HJ. Antiglycolipid antibodies in the diagnosis of autoimmune neuropathies. Rev Neurol 2001; 158:6S16-6S20.
27. Nobile-Orazio E, Giannotta C, Briani C. Antiganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies. J Neuroimmunol 2010; 219:119-122.
28. Galban-Horcajo F, Fitzpatrick AM, Hutton AJ, et al. Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. Eur J Neurol 2012; 20:62-70.
29. Pestronk A, Chuquilin M, Choksi R. Motor neuropathies and serum IgM binding toNS6Sheparin disaccharide orGM1ganglioside. J Neurol Neurosurg Psychiatry 2010; 81:726-760.
30. Muley SA, Parry G. Multifocal motor neuropathy. J Clin Neurosci 2012; 19:1201-1209.
31. Meuth SG, Kleinschnitz C. Multifocal motor neuropathy: Update on clinical characteristics, pathophysiological concepts and therapeutic options. Eur Neurol 2010; 63:193-204.
32. Echaniz-Laguna A, Dieteman JL. Seeing the blocks: MRI of the brachial plexus in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2011; 82:728.
33. Cats EA, Bertens AS, Veldink JH, et al. Associated autoimmune diseases in patients with multifocal motor neuropathy and their family members. J Neurol 2012; 259:1137-1141.
34. Sutedja NA, Otten HG, Cats EA, et al. Increased frequency of HLA-DRB1-15 in patients with multifocal motor neuropathy. Neurology 2010; 74:828-832.
35. Léger JM, Vargas S, Lievens I. Efficacy of intravenous immunoglobulin in multifocal motor neuropathy. Ann N Y Acad Sci 2007; 1110:248-255.
36. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology 1994; 44:429-432.
37. Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995; 59:248-252.
38. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study. Neurology 2000; 55:1256-1262.
39. Léger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled study. Brain 2001; 124:145-153.
40. Piepers S, Jansen MD, Cats EA, et al. IVIg inhibits classical pathway activity and anti-GM1 IGM-mediated complement deposition in MMN. J Neuroimmunol 2010; 229:256-262.
41. Yuki N, Watanabe H, Nakajima T, Spä th PJ. IVIg blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2011; 82:87-91.
42. Van der Pol W, Cats EA, Van den Berg LH. Intravenous immunoglobulin treatment in multifocal motor neuropathy. J Clin Immunol 2010; 30:S79-S83.
43. Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH. Multifocal motor neuropathy: Long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002; 125:1875-1886.
44. Terenghi F, Cappellari A, Bersano A, et al. How long is IVIg effective in multifocal motor neuropathy?. Neurology 2004; 62:666-668.
45. Vucic S, Black KR, Chong PS, Cros D.Multifocal motor neuropathy: Decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004; 63:1264-1269.
46. Léger JM, Viala K, Cancalon F, et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: A retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry 2008; 79:93-96.
47. Harbo T, Andersen H, Jakobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology 2010; 75:1377-1380.
48. Misbah SA, Baumann A, Fazio R, et al. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: A open-label proof-of-concept study. J Peripher Nerv Syst 2011; 16:92-97.
49. Piepers S, Van den Berg-Vos R, Van der Pol WL, et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: A randomized, controlled trial. Brain 2007; 130 (Pt 8):2004-2010.
50. Umapathi T, Hughes RAC, Nobile-Orazio E, Léger JM. Immunosupressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Libr 2012; 4:CD003217.
51. Chaudry V, Cornblath DR. An open-label trial of rituximab (Rituxan) in multifocal motor neuropathy. J Peripher Nerv Syst 2010; 15:196-201.
52. Michaud A, Delmont E, Jeandel PY, Desnuelle C. Improvement of severe and intravenous immunoglobulin-dependent multifocal motor neuropathy with conduction block after long-term rituximab. Rev Neurol 2011; 167:916-920.
53. Eftimov F, Van Schik IN. Immunotherapy of multifocal motor neuropathy. Expert Opin Biol Ther 2011; 11:329-342.
54. Fitzpatrick AM, Mann CA, Barry S, et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst 2011; 16:84-91.